US 11202787
Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
granted A61KA61K31/567A61K31/585
Quick answer
US patent 11202787 (Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients) held by Corcept Therapeutics Incorporated expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/567, A61K31/585, A61P, A61P3/10